Mitigation of influenza-mediated inflammation by immunomodulatory matrix-bound nanovesicles.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 37205761.
- Also identified by DOI 10.1126/sciadv.adf9016 and PMC identifier 10198633.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
Cytokine storm describes a life-threatening, systemic inflammatory syndrome characterized by elevated levels of proinflammatory cytokines and immune cell hyperactivation associated with multi-organ dysfunction. Matrix-bound nanovesicles (MBV) are a subclass of extracellular vesicle shown to down-regulate proinflammatory immune responses. The objective of this study was to assess the efficacy of MBV in mediating influenza-induced acute respiratory distress syndrome and cytokine storm in a murine model. Intravenous administration of MBV decreased influenza-mediated total lung inflammatory cell density, proinflammatory macrophage frequencies, and proinflammatory cytokines at 7 and 21 days following viral inoculation. MBV decreased long-lasting alveolitis and the proportion of lung undergoing inflammatory tissue repair at day 21. MBV increased the proportion of activated anti-viral CD4<sup>+</sup> and CD8<sup>+</sup> T cells at day 7 and memory-like CD62L<sup>+</sup> CD44<sup>+</sup>, CD4<sup>+</sup>, and CD8<sup>+</sup> T cells at day 21. These results show immunomodulatory properties of MBV that may benefit the treatment of viral-mediated pulmonary inflammation with applicability to other viral diseases such as SARS-CoV-2.
Medical subject headings
- Influenza, Human
- COVID-19